238 related articles for article (PubMed ID: 33922276)
1. Modeling Sialidosis with Neural Precursor Cells Derived from Patient-Derived Induced Pluripotent Stem Cells.
Seol B; Kim YD; Cho YS
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922276
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and molecular characterization of novel mutations in GLB1 and NEU1 in patient cells with lysosomal storage disorders.
Kwak JE; Son MY; Son YS; Son MJ; Cho YS
Biochem Biophys Res Commun; 2015 Feb; 457(4):554-60. PubMed ID: 25600812
[TBL] [Abstract][Full Text] [Related]
3. Generation of novel induced pluripotent stem cell (iPSC) line from a 16-year-old sialidosis patient with NEU-1 gene mutation.
Liu SP; Hsu YH; Huang CY; Ho MC; Cheng YC; Wen CH; Lu HE; Tsai CH; Shyu WC; Hsieh PCH
Stem Cell Res; 2018 Apr; 28():39-43. PubMed ID: 29414417
[TBL] [Abstract][Full Text] [Related]
4. Generation of human induced pluripotent stem cells (hIPSCs) from sialidosis types I and II patients with pathogenic neuraminidase 1 mutations.
Han MJ; Annunziata I; Weesner J; Campos Y; Salie M; O'Reilly C; d'Azzo A
Stem Cell Res; 2020 Jul; 46():101836. PubMed ID: 32485644
[TBL] [Abstract][Full Text] [Related]
5. Splice donor site mutation in the lysosomal neuraminidase gene causing exon skipping and complete loss of enzyme activity in a sialidosis patient.
Penzel R; Uhl J; Kopitz J; Beck M; Otto HF; Cantz M
FEBS Lett; 2001 Jul; 501(2-3):135-8. PubMed ID: 11470272
[TBL] [Abstract][Full Text] [Related]
6. Elimination of abnormal sialylglycoproteins in fibroblasts with sialidosis and galactosialidosis by normal gene transfer and enzyme replacement.
Oheda Y; Kotani M; Murata M; Sakuraba H; Kadota Y; Tatano Y; Kuwahara J; Itoh K
Glycobiology; 2006 Apr; 16(4):271-80. PubMed ID: 16361247
[TBL] [Abstract][Full Text] [Related]
7. Molecular pathology of NEU1 gene in sialidosis.
Seyrantepe V; Poupetova H; Froissart R; Zabot MT; Maire I; Pshezhetsky AV
Hum Mutat; 2003 Nov; 22(5):343-52. PubMed ID: 14517945
[TBL] [Abstract][Full Text] [Related]
8. Type I sialidosis, a normosomatic lysosomal disease, in the differential diagnosis of late-onset ataxia and myoclonus: An overview.
Caciotti A; Melani F; Tonin R; Cellai L; Catarzi S; Procopio E; Chilleri C; Mavridou I; Michelakakis H; Fioravanti A; d'Azzo A; Guerrini R; Morrone A
Mol Genet Metab; 2020 Feb; 129(2):47-58. PubMed ID: 31711734
[TBL] [Abstract][Full Text] [Related]
9. Identification of a CTL4/Neu1 fusion transcript in a sialidosis patient.
Uhl J; Penzel R; Sergi C; Kopitz J; Otto HF; Cantz M
FEBS Lett; 2002 Jun; 521(1-3):19-23. PubMed ID: 12067718
[TBL] [Abstract][Full Text] [Related]
10. An iPSC-based neural model of sialidosis uncovers glycolytic impairment-causing presynaptic dysfunction and deregulation of Ca
Odaka H; Numakawa T; Soga M; Kido J; Matsumoto S; Kajihara R; Okumiya T; Tani N; Tanoue Y; Fukuda T; Furuya H; Inoue T; Era T
Neurobiol Dis; 2021 May; 152():105279. PubMed ID: 33516873
[TBL] [Abstract][Full Text] [Related]
11. Neu4, a novel human lysosomal lumen sialidase, confers normal phenotype to sialidosis and galactosialidosis cells.
Seyrantepe V; Landry K; Trudel S; Hassan JA; Morales CR; Pshezhetsky AV
J Biol Chem; 2004 Aug; 279(35):37021-9. PubMed ID: 15213228
[TBL] [Abstract][Full Text] [Related]
12. Clinical and electrophysiological characteristics of a type 1 sialidosis patient with a novel deletion mutation in NEU1 gene.
Fan SP; Lee NC; Lin CH
J Formos Med Assoc; 2020 Jan; 119(1 Pt 3):406-412. PubMed ID: 31371146
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy corrects the neurological deficits of mice with sialidosis.
Hwu WL; Chang K; Liu YH; Wang HC; Lee NC; Chien YH
Gene Ther; 2024 May; 31(5-6):263-272. PubMed ID: 38321198
[TBL] [Abstract][Full Text] [Related]
14. In silico identification of new putative pathogenic variants in the NEU1 sialidase gene affecting enzyme function and subcellular localization.
Bonardi D; Ravasio V; Borsani G; d'Azzo A; Bresciani R; Monti E; Giacopuzzi E
PLoS One; 2014; 9(8):e104229. PubMed ID: 25153125
[TBL] [Abstract][Full Text] [Related]
15. Mutations in sialidosis impair sialidase binding to the lysosomal multienzyme complex.
Lukong KE; Landry K; Elsliger MA; Chang Y; Lefrancois S; Morales CR; Pshezhetsky AV
J Biol Chem; 2001 May; 276(20):17286-90. PubMed ID: 11279074
[TBL] [Abstract][Full Text] [Related]
16. Lysosomal sialidase NEU1, its intracellular properties, deficiency, and use as a therapeutic agent.
Itoh K; Tsukimoto J
Glycoconj J; 2023 Dec; 40(6):611-619. PubMed ID: 38147151
[TBL] [Abstract][Full Text] [Related]
17. Short-term, high dose enzyme replacement therapy in sialidosis mice.
Wang D; Bonten EJ; Yogalingam G; Mann L; d'Azzo A
Mol Genet Metab; 2005 Jul; 85(3):181-9. PubMed ID: 15979029
[TBL] [Abstract][Full Text] [Related]
18. Chaperone-mediated gene therapy with recombinant AAV-PPCA in a new mouse model of type I sialidosis.
Bonten EJ; Yogalingam G; Hu H; Gomero E; van de Vlekkert D; d'Azzo A
Biochim Biophys Acta; 2013 Oct; 1832(10):1784-92. PubMed ID: 23770387
[TBL] [Abstract][Full Text] [Related]
19. Type 1 Sialidosis Patient With a Novel Deletion Mutation in the NEU1 Gene: Case Report and Literature Review.
Ahn JH; Kim AR; Lee C; Kim NKD; Kim NS; Park WY; Kim M; Youn J; Cho JW; Kim JS
Cerebellum; 2019 Jun; 18(3):659-664. PubMed ID: 30635863
[TBL] [Abstract][Full Text] [Related]
20. Five novel mutations in the lysosomal sialidase gene (NEU1) in type II sialidosis patients and assessment of their impact on enzyme activity and intracellular targeting using adenovirus-mediated expression.
Pattison S; Pankarican M; Rupar CA; Graham FL; Igdoura SA
Hum Mutat; 2004 Jan; 23(1):32-9. PubMed ID: 14695530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
